

Maud Combes^{*0}, Philippe Poindron^{*} and Noelle Callizot^{*1}

^{*}Department of Neuropharmacology, Neuro-Sys SAS, 410 Chemin Départemental 60, 13120 Gardanne, France - ⁰UPMC, 4 Place Jussieu, 75005 Paris, France - ¹nc@neuro-sys.fr / www.neuro-sys.fr

1 Introduction

Alzheimer disease (AD) affects mainly people over the age of 65 years, suffering from different clinical symptoms such as progressive decline in memory, thinking, language, and learning capacity. The toxic role of beta amyloid peptide (A β) has now shifted from insoluble A β fibrils to smaller, soluble oligomeric A β (A β O) fractions. Many evidences suggest that the neurodegenerative process would be due to the interaction of A β O with binding targets, activation of stress kinases, hyperphosphorylation of tau (τ) protein, caspase activation, loss of synapse, neuronal death, loss of cholinergic function, generation of reactive intermediates of oxygen (oxidative stress) or glutamate excitotoxicity. Urgent need for efficient new therapies is high, but could only be successful with an extensively comprehension of A β O degeneration process.

By modulating concentration and time of exposure to A β O, it was possible to reproduced their early effect (oxidative stress) and their long term structural alteration development (death of neurons); for review see Callizot et al., 2013. In the present study we investigated the neuroprotective mechanism of 17- β Estradiol (17- β E) on A β induced neurotoxicity.

2 Methods

Culture of cortical neurons: Rat cortical neurons (E15) were cultured as described by Singer et al., 1999. The cells were seeded at a density of 30,000 per well in 96-well plates (for immunostaining) and of 170,000 per well in 24-well plates (for Western-blot (WB)) precoated with poly-L-lysine and cultured at 37°C in an air (95%) – CO₂ (5%) incubator. Six wells were used per condition.

Pharmacological treatments: The cortical neurons were treated with A β solution (10 μ mol/L) after 11 days of culture. The human A β -1-42 preparation was done following the procedure described by Callizot et al., 2013. 2h before addition of A β , the cells were incubated with different inhibitors. 17- β E was used at 100 nmol/L and was added as pretreatment (1h before A β addition).

Immunostaining: After 24 h of A β treatment, cells were fixed by a solution of ethanol (95%) acetic acid (5%). The cells were incubated with monoclonal anti-microtubule-associated-protein 2 (MAP-2) antibody that was revealed with Alexa Fluor 488 goat anti-mouse IgG. The immuno-labelled cultures were examined with MetaXpress (Molecular Devices) at X 20 magnification.

Westernblotting: After 8 and 24 h of A β treatment, cells were lysed with cellytic and immediately frozen at -80°C. All reagents were prepared and used according to manufacturer's recommendations (Simon[™] - ProteinSimple - www.proteinsimple.com). Anti-phospho- τ , anti-phospho-AKT primary antibodies were used for WB analysis.


4 Conclusions

We showed in this study :


1. 17- β E was able to protect neurons from A β O injuries;
2. This protective effect involved the receptor Er β ;
3. 17- β E was able via its own receptor to activate the anti-apoptotic and the DNA repair pathway;
4. The putative mode of action of 17- β E was summarized into the drawing below by red arrows.

3 Results







17- β E (100 nM) was able to significantly protect neurons from A β injuries (10 μ M for 24h) and reduced the τ -phosphorylation



Quantification of τ -phospho in cell lysate after a 8h A β (10 μ M) application: Effect of 17- β E



Investigation of the neuroprotective effect of 17 β E in presence of inhibitors



Quantification of AKT-phospho in cell lysate after a 24h A β (10 μ M) application: Effect of 17- β E

